Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ligand Pharmaceuticals Incorporated (LGND) Earnings: Report Dates and Results
Ligand Pharmaceuticals (LGND) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Ligand Pharmaceuticals reported EPS of -$1.43, below the $1.42 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LGND has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 40.1% above the $2.12 reported for the quarter ended Dec 31, 2025.
LGND Earnings Call
The latest LGND earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, LGND beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $78.75M, down 31.8% from $115.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.43 | $1.42 | N/A | -200.70% | Miss | -146.3% | 10 | 0 up, 1 down | Oct 29, 2026 | $78.75M |
| Jun 30, 2026 | $2.22 | $1.34 | N/A | +65.67% | Beat | +825.0% | 9 | 0 up, 2 down | Aug 6, 2026 | $63.69M |
| Mar 31, 2026 | $1.63 | $1.80 | $1.66 - $1.96 | -9.44% | Miss | +22.6% | 6 | 0 up, 4 down | May 14, 2026 | $51.72M |
| Dec 31, 2025 | $2.12 | $0.63 | N/A | +236.51% | Beat | +66.9% | 7 | 3 up, 1 down | Feb 26, 2026 | $59.67M |
| Sep 30, 2025 | $3.09 | $1.93 | $1.60 - $2.09 | +60.10% | Beat | +67.9% | 6 | 2 up, 1 down | Nov 6, 2025 | $115.46M |
| Jun 30, 2025 | $0.24 | $0.21 | N/A | +14.29% | Beat | -82.9% | 7 | 0 up, 5 down | Aug 7, 2025 | $47.63M |
| Mar 31, 2025 | $1.33 | $1.21 | $1.14 - $1.27 | +9.92% | Beat | +10.8% | 4 | 0 up, 2 down | May 8, 2025 | $45.33M |
| Dec 31, 2024 | $1.27 | $1.19 | $1.05 - $1.35 | +6.71% | Beat | -8.0% | 7 | 1 up, 1 down | Feb 27, 2025 | $42.81M |
| Sep 30, 2024 | $1.84 | $1.35 | $1.17 - $1.68 | +36.30% | Beat | +80.4% | 7 | 1 up, 0 down | Nov 7, 2024 | $51.81M |
| Jun 30, 2024 | $1.40 | $1.06 | $0.94 - $1.36 | +32.08% | Beat | -1.4% | 5 | 0 up, 0 down | Aug 6, 2024 | $41.53M |
| Mar 31, 2024 | $1.20 | $0.83 | $0.56 - $0.93 | +44.58% | Beat | -47.4% | 5 | 0 up, 0 down | May 7, 2024 | $30.98M |
| Dec 31, 2023 | $1.38 | $0.66 | $0.63 - $0.68 | +109.09% | Beat | +1.5% | 4 | 0 up, 0 down | Feb 27, 2024 | $28.10M |
| Sep 30, 2023 | $1.02 | $0.62 | $0.46 - $0.70 | +64.52% | Beat | -22.1% | 4 | 0 up, 0 down | Nov 8, 2023 | $32.87M |
| Jun 30, 2023 | $1.42 | $0.66 | $0.61 - $0.68 | +115.15% | Beat | +37.9% | 4 | 1 up, 0 down | Aug 8, 2023 | $26.37M |
| Mar 31, 2023 | $2.28 | $0.89 | $0.52 - $1.13 | +156.18% | Beat | +200.0% | 5 | 1 up, 0 down | May 4, 2023 | $43.98M |
| Dec 31, 2022 | $1.36 | $1.19 | $1.04 - $1.30 | +14.29% | Beat | -24.4% | 4 | 1 up, 0 down | Feb 22, 2023 | $50.38M |
| Sep 30, 2022 | $1.31 | $0.43 | $0.38 - $0.46 | +204.65% | Beat | -17.1% | 5 | 0 up, 0 down | Nov 7, 2022 | $59.22M |
| Jun 30, 2022 | $1.03 | $0.43 | $0.06 - $0.70 | +139.53% | Beat | -36.8% | 5 | 0 up, 0 down | Aug 8, 2022 | $50.13M |
| Mar 31, 2022 | $0.76 | $0.66 | $0.44 - $0.89 | +15.15% | Beat | -46.1% | 6 | 0 up, 0 down | May 4, 2022 | $36.52M |
| Dec 31, 2021 | $1.80 | $1.37 | $1.33 - $1.43 | +31.39% | Beat | +11.1% | 6 | N/A | Feb 17, 2022 | $36.88M |
| Sep 30, 2021 | $1.58 | $1.04 | $0.88 - $1.31 | +51.92% | Beat | +51.9% | 6 | 0 up, 0 down | Nov 9, 2021 | $64.83M |
| Jun 30, 2021 | $1.63 | $1.36 | $1.10 - $1.53 | +19.85% | Beat | +63.0% | 6 | N/A | Jul 29, 2021 | $84.67M |
| Mar 31, 2021 | $1.41 | $1.13 | $1.05 - $1.19 | +24.78% | Beat | +58.4% | 6 | N/A | May 3, 2021 | $55.15M |
| Dec 31, 2020 | $1.62 | $1.09 | N/A | +48.62% | Beat | +128.2% | 6 | N/A | Feb 3, 2021 | $47.13M |
| Sep 30, 2020 | $1.04 | $0.98 | $0.84 - $1.07 | +6.12% | Beat | +112.2% | 6 | N/A | Oct 30, 2020 | $41.85M |
| Jun 30, 2020 | $1.00 | $0.76 | $0.65 - $0.97 | +31.58% | Beat | +47.1% | 6 | N/A | Aug 3, 2020 | $41.42M |
| Mar 31, 2020 | $0.89 | $0.66 | $0.59 - $0.82 | +34.85% | Beat | -23.3% | 6 | N/A | May 6, 2020 | $33.16M |
| Dec 31, 2019 | $0.71 | $0.65 | $0.58 - $0.68 | +9.23% | Beat | -58.2% | 4 | N/A | Feb 6, 2020 | $27.00M |
| Sep 30, 2019 | $0.49 | $0.62 | $0.54 - $0.65 | -20.97% | Miss | -62.9% | 4 | N/A | Nov 5, 2019 | $24.81M |
| Jun 30, 2019 | $0.68 | $0.55 | $0.38 - $0.65 | +23.64% | Beat | -73.7% | 4 | N/A | Jul 30, 2019 | $24.99M |
| Mar 31, 2019 | $1.16 | $15.45 | N/A | -92.49% | Miss | -25.2% | 2 | N/A | May 2, 2019 | $43.48M |
| Dec 31, 2018 | $1.70 | $1.22 | $1.15 - $1.24 | +39.34% | Beat | +29.8% | 5 | N/A | Feb 7, 2019 | N/A |
| Sep 30, 2018 | $1.32 | $1.03 | $0.98 - $1.08 | +28.16% | Beat | +91.3% | 5 | N/A | Nov 8, 2018 | $45.66M |
| Jun 30, 2018 | $2.59 | $2.38 | N/A | +8.82% | Beat | +286.6% | 2 | N/A | Aug 6, 2018 | $90.04M |
| Mar 31, 2018 | $1.55 | $1.26 | $0.53 - $1.35 | +23.02% | Beat | +171.9% | 5 | N/A | May 8, 2018 | $56.16M |
| Dec 31, 2017 | $1.31 | $1.19 | $1.06 - $1.20 | +10.08% | Beat | +4.8% | 5 | N/A | Feb 21, 2018 | $50.47M |
| Sep 30, 2017 | $0.69 | $0.61 | $0.51 - $0.75 | +13.11% | Beat | +11.3% | 5 | N/A | Nov 9, 2017 | $33.38M |
| Jun 30, 2017 | $0.67 | $0.46 | $0.40 - $0.58 | +45.65% | Beat | +34.0% | 5 | N/A | Aug 7, 2017 | $28.00M |
| Mar 31, 2017 | $0.57 | $0.72 | N/A | -20.83% | Miss | -41.2% | N/A | N/A | May 9, 2017 | $29.27M |
| Dec 31, 2016 | $1.25 | $1.19 | N/A | +5.04% | Beat | +89.4% | N/A | N/A | Feb 23, 2017 | $38.19M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.78, up 18.7% from the year before. It was $3.34 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.78 | +18.7% |
| Dec 31, 2024 | $5.71 | -6.4% |
| Dec 31, 2023 | $6.10 | +36.8% |
| Dec 31, 2022 | $4.46 | -30.5% |
| Dec 31, 2021 | $6.42 | +41.1% |
| Dec 31, 2020 | $4.55 | +49.7% |
| Dec 31, 2019 | $3.04 | -57.5% |
| Dec 31, 2018 | $7.16 | +121.0% |
| Dec 31, 2017 | $3.24 | -3.0% |
| Dec 31, 2016 | $3.34 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,110 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,461 | 12 | |
| 2026Q1 | Mar 31, 2026 | 5,694 | 13 | |
| 2025Q4 | Dec 31, 2025 | 6,388 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,629 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,629 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,194 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,928 | 13 |
2026Q3 Earnings Call
Opening remarks
Melanie Herman Head of Investor Relations Good morning, everyone, and welcome to Ligand's Third Quarter 2026 Earnings Call. With me on the call today are CEO, Todd Davis; Chief Financial Officer, Tavo Espinoza; Vice President of Portfolio Strategy and Investments, Lauren Hay; and Paul Hadden, Senior Vice President of Investments and Business Development. During the call today, we will review the financial results released earlier today and provide commentary on our recent business development activity and partner portfolio, followed by a question-and-answer session. Before we get started, I would like to point out that we will be discussing non-GAAP results, which exclude certain items such as stock-based compensation, amortization of intangible assets, amortization or impairment of financial royalty assets, transaction costs, and gains or losses from derivative assets and mark-to-market changes in investments, amongst others. I encourage you to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP measures, which can be found in today's release available on our website. Reconciliations of forward-looking non-GAAP measures are not provided because of the unreasonable effort associated with providing such reconciliations due to the variability in the occurrence of the amounts of certain components thereof. We believe these adjusted measures provide valuable insight into our core operating performance, both historically and moving forward. Our earnings release and a link to today's webcast can be found in the Investor Relations section of our website at ligand.com. This call is being recorded, and the audio portion will be archived in the Investors section of our website. On today's call, we will make forward-looking statements regarding our financial results and other matters related to the company's business. Please refer to the safe harbor statement related to these forward-looking statements, which are subject to risks and uncertainties. We remind you that actual events or results may differ materially from those projected or discussed and that all forward-looking statements are based upon currently available information. Ligand assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Ligand files with the Securities and Exchange Commission, or SEC, that can be found on Ligand's website at ligand.com or on the SEC's website at sec.gov. And with that, I'd like to turn the call over to our CEO, Todd Davis.
Todd Davis CEO Thank you, Melanie, and good morning, everyone. We appreciate you joining us today. The third quarter was an important one for Ligand, with royalty revenue growing 51% year-over-year to approximately $70 million. Filspari, Ohtuvayre, and the addition of the XOMA commercial assets Vabysmo, Ojemda, and Miplyffa led that growth, with the Filspari launch in FSGS being a primary growth driver as well.
Frequently Asked Questions About LGND
When is Ligand Pharmaceuticals's next earnings date?
Ligand Pharmaceuticals's next earnings report is expected for Feb 24, 2027.
Did LGND beat earnings estimates last quarter?
No. Ligand Pharmaceuticals reported EPS of -$1.43 for the quarter ended Sep 30, 2026, below the $1.42 estimate by 200.70%.
What EPS do analysts expect from LGND next quarter?
The consensus EPS estimate for Ligand Pharmaceuticals for the quarter ending Dec 31, 2026 is $2.97 from 14 analysts, with estimates from $2.38 to $3.17.
How often does LGND beat earnings estimates?
Ligand Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +22.88%.
LGND pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors